Loss of Dnmt3a increases self-renewal and resistance to pegIFNα in JAK2-V617F-positive myeloproliferative neoplasms

被引:3
|
作者
Usart, Marc [1 ,2 ]
Stetka, Jan [1 ,2 ,3 ]
Paz, Damien Luque [4 ]
Hansen, Nils [1 ,2 ]
Kimmerlin, Quentin [1 ,2 ]
Fonseca, Tiago Almeida [1 ,2 ]
Lock, Melissa [1 ,2 ]
Kubovcakova, Lucia [1 ,2 ]
Karjalainen, Riikka [1 ,2 ]
Hao-Shen, Hui [1 ,2 ]
Boersch, Anastasiya [5 ,6 ,7 ]
El Taher, Athimed [5 ,6 ,7 ,8 ]
Schulz, Jessica [8 ]
Leroux, Jean-Christophe [8 ]
Dirnhofer, Stefan [9 ]
Skoda, Radek C. [1 ,2 ]
机构
[1] Univ Basel Hosp, Dept Biomed, Expt Hematol, Hebelstr 20, CH-4031 Basel, Switzerland
[2] Univ Basel, Hebelstr 20, CH-4031 Basel, Switzerland
[3] Palacky Univ, Fac Med & Dent, Dept Biol, Olomouc, Czech Republic
[4] Univ Angers, Nantes Univ, Ctr Hosp Univ Angers, Ctr Natl Rech Sci,Ctr Rech Cancerol & Immunol Inte, Angers, France
[5] Univ Basel, Dept Biomed, Bioinformat, Basel, Switzerland
[6] Univ Hosp Basel, Basel, Switzerland
[7] Swiss Inst Bioinformat, Basel, Switzerland
[8] ETH Honggerberg Zurich, Inst Pharmaceut Sci, Zurich, Switzerland
[9] Univ Hosp Basel, Inst Med Genet & Pathol, Basel, Switzerland
基金
瑞士国家科学基金会;
关键词
HEMATOPOIETIC STEM-CELLS; CLONAL HEMATOPOIESIS; POLYCYTHEMIA-VERA; INTERFERON-ALPHA; T-CELLS; MUTATIONS; JAK2-V617F; CLASSIFICATION; EXPRESSION; PROGNOSIS;
D O I
10.1182/blood.2023020270
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pegylated interferon alfa (pegIFN- alpha ) can induce molecular remissions in patients with JAK2 -V617F-positive myeloproliferative neoplasms (MPNs) by targeting long-term hematopoietic stem cells (LT-HSCs). Additional somatic mutations in genes regulating LT-HSC self-renewal, such as DNMT3A , have been reported to have poorer responses to pegIFN alpha . We investigated whether DNMT3A loss leads to alterations in JAK2 -V617F LTHSC functions conferring resistance to pegIFN alpha treatment in a mouse model of MPN and in hematopoietic progenitors from patients with MPN. Long -term treatment with pegIFN alpha normalized blood parameters and reduced splenomegaly and JAK2 -V617F chimerism in single -mutant JAK2 -V617F ( VF ) mice. However, pegIFN alpha in VF ; Dnmt3a Delta / Delta ( VF;Dm Delta / Delta ) mice worsened splenomegaly and failed to reduce JAK2 -V617F chimerism. Furthermore, LT-HSCs from VF;Dm Delta / Delta mice compared with VF were less prone to accumulate DNA damage and exit dormancy upon pegIFN alpha treatment. RNA sequencing showed that IFN alpha induced stronger upregulation of in fl ammatory pathways in LT-HSCs from VF;Dm Delta / Delta than from VF mice, indicating that the resistance of VF;Dm Delta / Delta LT-HSC was not due tofailure in IFN alpha signaling. Transplantations of bone marrow from pegIFN alpha - treated VF;Dm Delta / Delta mice gave rise to more aggressive disease in secondary and tertiary recipients. Liquid cultures of hematopoietic progenitors from patients with MPN with JAK2 -V617F and DNMT3A mutation showed increased percentages of JAK2 -V617F-positive colonies upon IFN alpha exposure, whereas in patients with JAK2 -V617F alone, the percentages of JAK2 -V617F-positive colonies decreased or remained unchanged. PegIFN- alpha combined with 5-azacytidine only partially overcame resistance in VF;Dm Delta / Delta mice. However, this combination strongly decreased the JAK2 -mutant allele burden in mice carrying VF mutation only, showing potential to in fl ict substantial damage preferentially to the JAK2 -mutant clone.
引用
收藏
页码:2490 / 2503
页数:14
相关论文
共 50 条
  • [21] JAK2V617F allele burden in patients with myeloproliferative neoplasms
    Alshemmari, Salem H.
    Rajaan, Reshmi
    Ameen, Reem
    Al-Drees, Mohammad A.
    Almosailleakh, Marwa R.
    ANNALS OF HEMATOLOGY, 2014, 93 (05) : 791 - 796
  • [22] JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms
    Choi, Daniel C.
    Messali, Nassima
    Uda, Narasimha Rao
    Abu-Zeinah, Ghaith
    Kermani, Pouneh
    Yabut, Maria Mia
    Lischer, Heidi E. L.
    Tokumori, Franco Castillo
    Erdos, Katie
    Lehmann, Thomas
    Sobas, Marta
    Rao, Tata Nageswara
    Scandura, Joseph M.
    LEUKEMIA, 2024, 38 (11) : 2487 - 2491
  • [23] Loss of Socs2 improves molecular responses to IFNα in a mouse model of myeloproliferative neoplasms driven by JAK2-V617F
    Usart, Marc
    Kimmerlin, Quentin
    Stetka, Jan
    Stoll, Cedric
    Rai, Shivam
    Fonseca, Tiago Almeida
    Karjalainen, Riikka
    Hao-Shen, Hui
    Roux, Julien
    El Taher, Athimed
    Lynch, Dylan
    Makukhin, Nikolai
    Ciulli, Alessio
    Skoda, Radek C.
    LEUKEMIA, 2025, : 876 - 887
  • [24] JAK2V617F-mutant vascular niche contributes to JAK2V617F clonal expansion in myeloproliferative neoplasms
    Lin, Chi Hua Sarah
    Kaushansky, Kenneth
    Zhan, Huichun
    BLOOD CELLS MOLECULES AND DISEASES, 2016, 62 : 42 - 48
  • [25] JAK2 and MPL gene mutations in V617F-negative myeloproliferative neoplasms
    Siemiatkowska, Anna
    Bieniaszewska, Maria
    Hellmann, Andrzej
    Limon, Janusz
    LEUKEMIA RESEARCH, 2010, 34 (03) : 387 - 389
  • [26] JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms
    Oh, Stephen T.
    Gotlib, Jason
    EXPERT REVIEW OF HEMATOLOGY, 2010, 3 (03) : 323 - 337
  • [27] JAK2V617F homozygosity drives a phenotypic switch in myeloproliferative neoplasms, but is insufficient to sustain disease
    Li, Juan
    Kent, David G.
    Godfrey, Anna L.
    Manning, Harriet
    Nangalia, Jyoti
    Aziz, Athar
    Chen, Edwin
    Saeb-Parsy, Kourosh
    Fink, Juergen
    Sneade, Rachel
    Hamilton, Tina L.
    Pask, Dean C.
    Silber, Yvonne
    Zhao, Xiaodong
    Ghevaert, Cedric
    Liu, Pentao
    Green, Anthony R.
    BLOOD, 2014, 123 (20) : 3139 - 3151
  • [28] Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
    Gou, Panhong
    Liu, Duanya
    Ganesan, Saravanan
    Lauret, Evelyne
    Maslah, Nabih
    Parietti, Veronique
    Zhang, Wenchao
    Meignin, Veronique
    Kiladjian, Jean-Jacques
    Cassinat, Bruno
    Giraudier, Stephane
    BLOOD CANCER JOURNAL, 2024, 14 (01)
  • [29] CALR mutations in a cohort of JAK2 V617F negative patients with suspected myeloproliferative neoplasms
    Mikic, Tanja Belcic
    Pajic, Tadej
    Sever, Matjaz
    SCIENTIFIC REPORTS, 2019, 9 (1)
  • [30] Angiogenesis in JAK2 V617F positive myeloproliferative neoplasms and ruxolitinib decrease VEGF, HIF-1 enesis in JAK2 V617F positive cells
    Cheng, Zhiyong
    Fu, Jianzhu
    Liu, Guimin
    Zhang, Lijun
    Xu, Qian
    Wang, Su-yun
    LEUKEMIA & LYMPHOMA, 2018, 59 (01) : 196 - 203